Jasper Therapeutics Weighs Sale as Cash Dwindles, Drug's Fate Uncertain

REDWOOD CITY, CA – June 01, 2026 – Clinical-stage biotechnology firm Jasper Therapeutics, Inc. announced today it has begun a comprehensive review of strategic alternatives, a move that puts the company's future—and the fate of its promising lead drug candidate, briquilimab—in serious question. The options on the table range from a sale of the company or its assets to a potential merger or, most ominously, an "orderly wind-down of operations."

The announcement, framed as a measure to "maximize shareholder value," highlights a stark reality increasingly common in the biotech sector: promising science is often not enough to survive harsh market conditions and the relentless need for capital.

A Biotech on the Brink

Jasper's decision follows what its Board of Directors called an "evaluation of current market conditions." For industry observers, the writing has been on the wall. The company's financial position has become increasingly precarious, a fact underscored by the dramatic 85% plunge in its stock price (NASDAQ: JSPR) over the past year. Shares now trade at just $0.83, leaving the company with a market capitalization of a mere $23.21 million.

The financial strain is acute. According to its latest filings, Jasper's cash and cash equivalents stood at just $14.1 million at the end of the first quarter of 2026, a sharp decline from $28.7 million at the end of 2025. With a negative levered free cash flow of nearly $69 million, the company is burning through its remaining reserves at an alarming rate. SEC filings have explicitly warned of an "imminent need to raise additional funding" simply to continue operations, let alone fund its planned pivotal trials.

This dire financial picture has led analysts to take a cautious stance. TD Cowen recently downgraded the stock from "Buy" to "Hold," and the consensus rating among analysts is a tepid "Hold." The inclusion of a potential "wind-down" in the strategic review has only amplified investor concerns, signaling that the company sees its own dissolution as a plausible outcome.

The Promise of Briquilimab

Lost in the financial turmoil is the significant clinical promise of Jasper's lead asset, briquilimab. The novel antibody therapy targets c-Kit (CD117), a receptor critical for the survival of mast cells, the underlying drivers of inflammation in a host of allergic diseases.

Briquilimab has produced impressive results in clinical trials for chronic urticaria, a debilitating condition characterized by persistent hives and swelling. Updated data from its Phase 1b/2a BEACON study for chronic spontaneous urticaria (CSU) showed that 67% of patients in one cohort achieved a complete response—defined as a total absence of symptoms—at 12 weeks. Across a larger group of 36 patients, 58% achieved a complete response, and 75% had their disease well-controlled.

Similar positive outcomes were seen in patients with chronic inducible urticaria (CIndU), a related condition triggered by physical stimuli. The drug has also shown encouraging preliminary data in a Phase 1b study for allergic asthma, demonstrating a favorable safety profile while improving lung function.

These results position briquilimab as a potentially best-in-class treatment in multi-billion dollar markets. The global market for CSU alone was valued at over $11 billion in 2025 and is projected to double within a decade. The asthma market is even larger, estimated at approximately $27 billion in 2024.

A Desperate Search for a Lifeline

Jasper Therapeutics now finds itself in a classic biotech paradox: it holds a potentially valuable asset but lacks the financial runway to bring it to market. The company's cash reserves are insufficient to fund the planned pivotal Phase 2b/3 study in CSU, a critical and expensive step toward regulatory approval.

The strategic review is, therefore, a desperate search for a lifeline. The most optimistic outcome for shareholders and patients would be an acquisition by a larger pharmaceutical company. The current biopharma M&A landscape offers a glimmer of hope. After a quiet period, deal-making has returned, with major players like Eli Lilly, Johnson & Johnson, and Pfizer making multi-billion dollar acquisitions in 2025 and 2026 to bolster their pipelines ahead of patent cliffs.

Immunology and respiratory diseases are hot areas for M&A, and a derisked, later-stage asset like briquilimab could be an attractive target for a company with a strong presence in these fields. A larger partner could provide the capital and infrastructure necessary to complete clinical development and navigate the complex regulatory and commercial launch processes.

Other possibilities, such as licensing the rights to briquilimab or entering a strategic collaboration, could also provide a much-needed cash infusion. However, these options would likely offer less upside to Jasper's long-suffering shareholders than an outright sale.

Patients and Investors in Limbo

The uncertainty surrounding Jasper's future leaves both patients and investors in a state of suspended animation. For the millions of people suffering from chronic urticaria and severe asthma, the potential delay or cancellation of briquilimab's development is a significant blow. The drug's novel mechanism offers hope for those who have failed to find relief with existing therapies.

For investors, the path forward is fraught with risk. While an acquisition could deliver a premium over the current depressed stock price, a wind-down scenario would likely result in a near-total loss of their investment. The company has given no timeline for its review, stating only that it does not intend to disclose further developments "unless and until its Board of Directors has approved a specific action."

For now, patients, investors, and the company itself can only wait to see if a lifeline will emerge from the strategic review, or if the promise of briquilimab will dissolve along with Jasper's remaining cash.